Novavax CEO Stanley Erck said he believes the last quarter was "the most significant in Novavax corporate history."
The reason? Vaccines, specifically clinical results from the Gaithersburg company's two lead vaccine programs: RSV for infants via maternal immunization and NanoFlu for seasonal flu.